Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 197

Sort by

Sort Order Select

Journal Articles

Donor Age Matters in Haploidentical Donor Transplantation Rather Than in Matched Unrelated Donor Transplantation in Older Adults with Acute Myeloid Leukemia

Ka Young Kim, Daehun Kwag, Gi-June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong-Wook Lee, Byung-Sik Cho, Heeje Kim

Blood (2023) 142 (Supplement 1): 2213.

https://doi.org/10.1182/blood-2023-188167

Published: 2023

Journal Articles

GATA-1 and BCL11A Collaboratively Regulate Erythroid Gene Expression through HDAC1 Dependent Manner

Min Young Kim, Suming Huang, Yi Qiu

Blood (2023) 142 (Supplement 1): 2456.

https://doi.org/10.1182/blood-2023-190084

Published: 2023

Journal Articles

TP53 Mutational Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification By Who 2022 and ICC Criteria - a Korean Multi-Center Study

Hyun-Young Kim, Boram Kim, Jayoung Lee, Shinae You, In-Suk Kim, Hyerin Kim, Hyerim Kim, Jee-Soo Lee, Yoon Hwan Chang, Hyunkyung Kim, Saeam Shin, Yu Jeong Choi, Miyoung Kim, Young-Uk Cho, Seongsoo Jang, Byunggyu Bae, Jong-Mi Lee, Yonggoo Kim, Myungshin Kim

Blood (2023) 142 (Supplement 1): 4222.

https://doi.org/10.1182/blood-2023-188935

Published: 2023

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

Correlation between Clinical Diagnosis and Histopathological Findings of Liver Dysfunction after Allogeneic-HSCT

Ka Young Kim, Jung Yeon Lee, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong-Wook Lee, Jae-Ho Yoon

Blood (2023) 142 (Supplement 1): 6999.

https://doi.org/10.1182/blood-2023-185518

Published: 2023

Journal Articles

Anti-Myeloma Effect of Compound K and Rh2 in a Multiple Myeloma Xenograft Model

Hye Ran Kim, Young Eun Lee, Jin Young Kim, Yong Jun Choi, Ju Heon Park, Jong Hee Shin, Myung-Geun Shin

Blood (2022) 140 (Supplement 1): 12469–12470.

https://doi.org/10.1182/blood-2022-156859

Published: 2022

Journal Articles

GATA-1 Acetylation Negatively Regulates Erythroid Differentiation

Min Young Kim, Suming Huang, Min Young Kim

Blood (2022) 140 (Supplement 1): 2447.

https://doi.org/10.1182/blood-2022-162684

Published: 2022

Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 2329–2332.

https://doi.org/10.1182/blood-2022-164772

Published: 2022

Journal Articles

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Blood (2021) 138 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2021-152008

Published: 2021

Journal Articles

A Retrospective Analysis of the Efficacy of Low-Dose Metronomic Cyclophosphamide for Treatment in Patients with Low Grade Non-Hodgkin Lymphoma

Boram Han, Bum Jun Kim, Ho Young Kim, Dae Young Zang, Hyun Lim, Ho Suk Kang, Jae Seung Soh, Hyo Jung Kim

Blood (2021) 138 (Supplement 1): 1361.

https://doi.org/10.1182/blood-2021-149484

Published: 2021

Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts

Blood (2021) 138 (10): 836–846.

https://doi.org/10.1182/blood.2020009578

Published: 2021

Includes: Supplemental data

Journal Articles

Venetoclax Crosses the Blood Brain Barrier: A Pharmacokinetic Analysis of the Cerebrospinal Fluid in Pediatric Leukemia Patients

Ahmed Hamed Salem, PhD FCP, Mohamed A Badawi, PhD, Andrew E. Place, MDPhD, Tammy L. Palenski, PhD, Richard Arrendale, PhD, Su Young Kim, Sara Federico, MD, Todd M. Cooper, DO, Rajeev Menon, PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137197

Published: 2020

Journal Articles

Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jeffrey E. Rubnitz, MD, Thomas B. Alexander, MDMPH, Theodore W. Laetsch, MD, Seong Lin Khaw, MD, Vinod A. Pullarkat, MD, Joseph T. Opferman, PhD, Kathryn G Roberts, PhD, Lindsey Rosenwinkel, Bo Tong, PhD, John C. Pesko, PhD, Mohamed Badawi, Deeksha Vishwamitra, PhD, Su Young Kim, Charles G Mullighan, MBBS, MD, Norman J. Lacayo, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-134582

Published: 2020

Journal Articles

Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships

Mohamed A Badawi, PhD, Sathej Gopalakrishnan, PhD, Benjamin Engelhardt, PhD, Tammy L. Palenski, PhD, Su Young Kim, Seth E. Karol, MD, Jeffrey E. Rubnitz, MD, Rajeev Menon, PhD, Ahmed Hamed Salem, PhD FCP

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139593

Published: 2020

Journal Articles

Ultrastructure of the Adult Hematopoietic Stem Cell Niche Defined Using Correlative Light and Electron Microscopy

Sobhika Agarwala, Keun-Young Kim, PhD, Sebastien Phan, Saeyeon Ju, Ye Eun Kong, Eric A Bushong, PhD, Mark H Ellisman, PhD, Owen J. Tamplin, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-141027

Published: 2020

Journal Articles

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Rosemary Anne Harrup, Carolyn Owen, MDFRCPC, James D'Rozario, Tadeusz Robak, MDPhD, Arnon P. Kater, Marco Montillo, Javier de la Serna, Marek Trněný, MD, Su Young Kim, Edward Bataillard, Marcus Lefebure, Michelle Boyer, John F. Seymour

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137415

Published: 2020

Journal Articles

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Brenda J Chyla, PhD, Relja Popovic, PhD, Charles Lu, PhD, Fengjiao Dunbar, PhD, Danjuma Quarless, PhD, Kenneth Robinson, MS, Scott Warder, PhD, Amanda Jacobson, PhD, Lang Zhou, PhD, Andrew Souers, PhD, Jeffrey Waring, PhD, Anahita Bhathena, PhD, Joel D. Leverson, PhD, Su Young Kim, MD PhD

Blood (2019) 134 (Supplement_1): 172.

https://doi.org/10.1182/blood-2019-127458

Published: 2019

Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 355.

https://doi.org/10.1182/blood-2019-123930

Published: 2019

Journal Articles

Probably Pathogenic KMT2D Variants Presenting with Cytopenias and Primary Immune Deficiency

Sun Young Kim, MD PhD, Alexander Ing, MS, CGC, Kristin Clemenz, MS, CGC, Kai Lee Yap, PhD, Sherif M. Badawy, MD, Robert I Liem, MD MS, Alexis A. Thompson, MD MPH, A. Kyle Mack, MD

Blood (2019) 134 (Supplement_1): 2334.

https://doi.org/10.1182/blood-2019-131468

Published: 2019

Journal Articles

The whole-genome landscape of Burkitt lymphoma subtypes

Blood (2019) 134 (19): 1598–1607.

https://doi.org/10.1182/blood.2019001880

Published: 2019

Includes: Supplemental data

NARROW

Donor Age Matters in Haploidentical Donor Transplantation Rather Than in Matched Unrelated Donor Transplantation in Older Adults with Acute Myeloid Leukemia

GATA-1 and BCL11A Collaboratively Regulate Erythroid Gene Expression through HDAC1 Dependent Manner

TP53 Mutational Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification By Who 2022 and ICC Criteria - a Korean Multi-Center Study

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Correlation between Clinical Diagnosis and Histopathological Findings of Liver Dysfunction after Allogeneic-HSCT

Anti-Myeloma Effect of Compound K and Rh2 in a Multiple Myeloma Xenograft Model

GATA-1 Acetylation Negatively Regulates Erythroid Differentiation

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

A Retrospective Analysis of the Efficacy of Low-Dose Metronomic Cyclophosphamide for Treatment in Patients with Low Grade Non-Hodgkin Lymphoma

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Venetoclax Crosses the Blood Brain Barrier: A Pharmacokinetic Analysis of the Cerebrospinal Fluid in Pediatric Leukemia Patients

Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships

Ultrastructure of the Adult Hematopoietic Stem Cell Niche Defined Using Correlative Light and Electron Microscopy

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Probably Pathogenic KMT2D Variants Presenting with Cytopenias and Primary Immune Deficiency

The whole-genome landscape of Burkitt lymphoma subtypes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only